Celgene Drops Crohn’s Disease Drug

October 24, 2017

Celgene abandoned development of its Crohn’s disease drug Revolve (mongersen) after disappointing results from a Phase III clinical trial.

The drug failed to pass muster in an interim futility analysis, the company said.

Celgene said it will continue development of other drugs for Crohn’s.

View today's stories